Lantheus Medcl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LANTHEUS MEDCL, and what generic alternatives to LANTHEUS MEDCL drugs are available?
LANTHEUS MEDCL has nine approved drugs.
There are nine US patents protecting LANTHEUS MEDCL drugs.
There are sixty-nine patent family members on LANTHEUS MEDCL drugs in seventeen countries and eight supplementary protection certificates in five countries.
Drugs and US Patents for Lantheus Medcl
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lantheus Medcl | THALLOUS CHLORIDE TL 201 | thallous chloride tl-201 | INJECTABLE;INTRAVENOUS | 017806-002 | Oct 9, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | 11,266,750 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lantheus Medcl | DEFINITY RT | perflutren | INJECTABLE;INTRAVENOUS | 021064-002 | Nov 17, 2020 | RX | Yes | Yes | 10,588,988 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | 10,583,207 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lantheus Medcl
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lantheus Medcl | CARDIOLITE | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-001 | Dec 21, 1990 | 4,894,445 | ⤷ Try a Trial |
Lantheus Medcl | CARDIOLITE | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-001 | Dec 21, 1990 | 4,988,827*PED | ⤷ Try a Trial |
Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | 6,146,657 | ⤷ Try a Trial |
Lantheus Medcl | CARDIOLITE | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-001 | Dec 21, 1990 | 5,324,824 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Lantheus Medcl Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Taiwan | I745282 | ⤷ Try a Trial |
China | 109562194 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2017192910 | ⤷ Try a Trial |
South Korea | 20170098880 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lantheus Medcl Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0712293 | 0790017-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920 |
0806968 | PA2007003 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005 |
0806968 | SPC/GB07/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
1178838 | 300736 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.